6533b7d3fe1ef96bd125fee3

RESEARCH PRODUCT

Comparison of DPP‐4 inhibition versus GLP‐1 analogue supplementation on survival and vascular complications in experimental sepsis (145.2)

Saule AgdauletovaMichael MaderThomas MünzelYuliya MikhedAmanda PfefferSebastian StevenMichael HausdingEberhard SchulzAndreas DaiberMatthias OelzeSwenja Kröller-schönThomas KleinPhilipp WelschofPaul Stamm

subject

DrugPathologymedicine.medical_specialtyendocrine system diseasesbusiness.industrymedia_common.quotation_subjectnutritional and metabolic diseasesPharmacologymedicine.diseaseBiochemistryDipeptidyl peptidaseSepsisGeneticsmedicineGLP-1 AnaloguebusinessMolecular BiologyDipeptidyl peptidase-4Biotechnologymedia_common

description

Background: Dipeptidyl peptidase [DPP]-4 inhibitors are a new class of drug for the treatment of hyperglycemia and recent studies revealed anti-inflammatory effects of these gliptins in experimenta...

https://doi.org/10.1096/fasebj.28.1_supplement.145.2